RARE — ULTRAGENYX PHARMACEUTICAL IN

Ownership history in EntryPoint Capital, LLC  ·  6 quarters on record

This page tracks every 13F SEC filing in which EntryPoint Capital, LLC reported a position in ULTRAGENYX PHARMACEUTICAL IN (RARE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.19% (2025 Q2)
Avg. % of fund
0.13%
First filed
2024 Q1
Last filed
2025 Q3
Quarters held
6
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 11,466 +891 +8.4% 0.13% $345K $30.08
2025 Q2 REDUCED 10,575 -407 -3.7% 0.19% $385K $36.36
2025 Q1 ADDED 10,982 +4,043 +58.3% 0.18% $398K $36.21
2024 Q4 ADDED 6,939 +4,408 +174.2% 0.12% $292K $42.07
2 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    RARE price (monthly, adj. close)

Other funds also holding RARE

As of 2025 Q4 — sorted by position size

GordonMD Global Investments LP 5.43% B Group, Inc. 2.29% GREAT POINT PARTNERS LLC 3Y 7Y 2.24% Stonepine Capital Management, LLC 3Y 7Y 1.68% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 1.56% Privium Fund Management B.V. 3Y 1.51% Rock Springs Capital Management LP 3Y 7Y 1.49% Palo Alto Investors LP 3Y 7Y 1.48% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 1.34% Krensavage Asset Management, LLC 3Y 7Y 1.22%
← Back to EntryPoint Capital, LLC Holdings